{"quote": {"result": [{"language": "en-US", "region": "US", "quoteType": "EQUITY", "typeDisp": "Equity", "quoteSourceName": "Delayed Quote", "triggerable": false, "customPriceAlertConfidence": "LOW", "currency": "EUR", "marketState": "REGULAR", "regularMarketChangePercent": -3.7735815, "regularMarketPrice": 1.02, "exchange": "FRA", "shortName": "OUTLOOK THERAPEUT. DL-,01", "longName": "Outlook Therapeutics, Inc.", "messageBoardId": "finmb_145859589", "exchangeTimezoneName": "Europe/Berlin", "exchangeTimezoneShortName": "CEST", "gmtOffSetMilliseconds": 7200000, "market": "dr_market", "esgPopulated": false, "regularMarketTime": 1683875702, "earningsTimestamp": 1676379900, "earningsTimestampStart": 1683894600, "earningsTimestampEnd": 1684153800, "trailingAnnualDividendRate": 0.0, "trailingAnnualDividendYield": 0.0, "epsTrailingTwelveMonths": -0.29, "epsForward": -0.23, "epsCurrentYear": -0.31, "priceEpsCurrentYear": -3.2903225, "sharesOutstanding": 256667008, "bookValue": 0.061, "fiftyDayAverage": 0.981066, "fiftyDayAverageChange": 0.038933992, "fiftyDayAverageChangePercent": 0.039685395, "twoHundredDayAverage": 1.103817, "twoHundredDayAverageChange": -0.083817005, "twoHundredDayAverageChangePercent": -0.07593379, "marketCap": 267792832, "forwardPE": -4.4347825, "priceToBook": 16.721312, "sourceInterval": 15, "exchangeDataDelayedBy": 15, "averageAnalystRating": "2.0 - Buy", "tradeable": false, "cryptoTradeable": false, "firstTradeDateMilliseconds": 1558418400000, "priceHint": 4, "regularMarketChange": -0.03999996, "regularMarketDayHigh": 1.02, "regularMarketDayRange": "1.02 - 1.02", "regularMarketDayLow": 1.02, "regularMarketVolume": 2909, "regularMarketPreviousClose": 1.06, "bid": 1.03, "ask": 1.05, "fullExchangeName": "Frankfurt", "financialCurrency": "USD", "regularMarketOpen": 1.02, "averageDailyVolume3Month": 49, "averageDailyVolume10Day": 0, "fiftyTwoWeekLowChange": 0.21899998, "fiftyTwoWeekLowChangePercent": 0.2734082, "fiftyTwoWeekRange": "0.801 - 1.55", "fiftyTwoWeekHighChange": -0.53, "fiftyTwoWeekHighChangePercent": -0.3419355, "fiftyTwoWeekLow": 0.801, "fiftyTwoWeekHigh": 1.55, "symbol": "41ON.F"}], "error": null}, "summary": {"result": [{"assetProfile": {"address1": "Building F", "address2": "Suite 320 485 Route 1 South", "city": "Iselin", "state": "NJ", "zip": "08852", "country": "United States", "phone": "609 619 3990", "website": "https://www.outlooktherapeutics.com", "industry": "Biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "longBusinessSummary": "Outlook Therapeutics, Inc., a late clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for various ophthalmic indications. Its lead product candidate is ONS-5010, an ophthalmic formulation of bevacizumab product candidate that is in Phase-III clinical trial for the treatment of wet age-related macular degeneration and other retina diseases. Outlook Therapeutics, Inc. has collaboration and license agreements with IPCA Laboratories Limited; Laboratorios Liomont, S.A. de C.V.; BioLexis Pte. Ltd.; and Zhejiang Huahai Pharmaceutical Co., Ltd. The company was formerly known as Oncobiologics, Inc. and changed its name to Outlook Therapeutics, Inc. in November 2018. Outlook Therapeutics, Inc. was incorporated in 2010 and is based in Iselin, New Jersey.", "fullTimeEmployees": 17, "companyOfficers": [{"maxAge": 1, "name": "Mr. Ralph H. Thurman", "age": 73, "title": "Independent Exec. Chairman", "yearBorn": 1949, "fiscalYear": 2022, "totalPay": {"raw": 205513, "fmt": "205.51k", "longFmt": "205,513"}, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Mr. C. Russell Trenary III", "age": 64, "title": "Pres, CEO & Director", "yearBorn": 1958, "fiscalYear": 2022, "totalPay": {"raw": 819530, "fmt": "819.53k", "longFmt": "819,530"}, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Mr. Lawrence A. Kenyon CPA", "age": 56, "title": "Exec. VP, CFO, Treasurer, Company Sec. & Director", "yearBorn": 1966, "fiscalYear": 2022, "totalPay": {"raw": 0, "fmt": null, "longFmt": "0"}, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Mr. Terry  Dagnon", "age": 60, "title": "Chief Operations Officer", "yearBorn": 1962, "fiscalYear": 2022, "totalPay": {"raw": 467225, "fmt": "467.23k", "longFmt": "467,225"}, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Mr. Jeffrey  Evanson", "age": 53, "title": "Chief Commercial Officer", "yearBorn": 1969, "fiscalYear": 2022, "totalPay": {"raw": 442231, "fmt": "442.23k", "longFmt": "442,231"}, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Ms. Alicia  Tozier", "title": "Sr. VP, Marketing & Market Access", "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Mr. Joel  Prieve", "title": "Sr. VP of Commercial Operations", "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Dr. Surendra  Sharma M.D.", "title": "Sr. VP of Medical Affairs", "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}], "auditRisk": 9, "boardRisk": 6, "compensationRisk": 10, "shareHolderRightsRisk": 8, "overallRisk": 10, "governanceEpochDate": 1682899200, "compensationAsOfEpochDate": 1672444800, "maxAge": 86400}}], "error": null}}